ECHOPULSE
no surgery-related risks
single session treatment
no scar
ECHOPULSE® is the first robotic and 100% non-invasive solution for echotherapy treatment (High-Intensity Focused Ultrasound HIFU) of thyroid nodules and breast fibroadenoma. The therapeutic ultrasound is combined with a standard ultrasound beam to control the accuracy of the treatment. It can be operated by a single person in a nonsurgical environment. It leaves no scars and maintains the thyroid function and the integrity of the breast tissue.
Lang B.; 2 year efficacy of single-session HIFU ablation of benign thyroid nodules; European Society of Radiology, 2018
Kovatcheva, R.; Long-term efficacy of ultrasound-guided HIFU treatment of fibroadenoma. J Ther Ultrasound 5,1 2017
ECHOPULSE® echotherapy targets the nodule through thermoablation. The robot’s treatment head combines a therapeutic ultrasound probe with a linear one: The therapeutic ultrasound probe delivers the HIFU (High-Intensity Focused Ultrasound) beam and focusses it to concentrated the thermal energy to the target. The linear probe allows real-time image visualization for a precise energy deposit.
Volume reductions of fibroadenoma after ECHOPULSE treatment can be expected to be around 70% after 12 months. Continued decrease in volume has been observed after this period.
Kovatcheva et al.; Ultrasound-guided high-intensity focused ultrasound treatment of breast fibroadenoma -a multicenter experience R. Journal of Therapeutic Ultrasound; 2015
ECHOPULSE® echotherapy targets the nodule through thermoablation. The robot’s treatment head combines a therapeutic ultrasound probe with a linear one: The therapeutic ultrasound probe delivers the HIFU (High-Intensity Focused Ultrasound) beam and focusses it to concentrated the thermal energy to the target. The linear probe allows real-time image visualization for a precise energy deposit.
Allowing a benign nodule to grow and become so large that there is no choice but to operate is a failure of medicine.
Dr. Pedro Pablo Ortiz Remacha, Endocrinologist and thyroid expert, Zaragoza, Spain
“Patients call from all over Germany and from outside Germany as well.”
Dr. Hans-Christian Kolberg, Head of the Department of Gynecology and Obstetrics Marienhospital Bottrop, Germany
Echopulse is a class IIb medical device (according to Directive 93/42/EEC) designed and marketed by Theraclion. Echopulse has received CE-mark for non-invasive treatment of breast fibroadenomas and thyroid nodules – CE n° 0120. Before use, read the instruction for use carefully.
